JP2023526973A5 - - Google Patents
Info
- Publication number
- JP2023526973A5 JP2023526973A5 JP2022571299A JP2022571299A JP2023526973A5 JP 2023526973 A5 JP2023526973 A5 JP 2023526973A5 JP 2022571299 A JP2022571299 A JP 2022571299A JP 2022571299 A JP2022571299 A JP 2022571299A JP 2023526973 A5 JP2023526973 A5 JP 2023526973A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid residues
- glp
- ala
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010472577.8 | 2020-05-29 | ||
| CN202010472577 | 2020-05-29 | ||
| CN202110335100 | 2021-03-29 | ||
| CN202110335100.X | 2021-03-29 | ||
| PCT/CN2021/096568 WO2021239082A1 (zh) | 2020-05-29 | 2021-05-28 | Glp-1和gip受体双重激动剂化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526973A JP2023526973A (ja) | 2023-06-26 |
| JP2023526973A5 true JP2023526973A5 (https=) | 2024-06-03 |
Family
ID=78745631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571299A Pending JP2023526973A (ja) | 2020-05-29 | 2021-05-28 | Ｇｌｐ－１とｇｉｐ受容体二重アゴニスト化合物及びその応用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230190879A1 (https=) |
| EP (1) | EP4159750A4 (https=) |
| JP (1) | JP2023526973A (https=) |
| KR (1) | KR20230018395A (https=) |
| CN (3) | CN114222755B (https=) |
| AU (1) | AU2021278157A1 (https=) |
| BR (1) | BR112022023834A2 (https=) |
| CA (1) | CA3180215A1 (https=) |
| MX (1) | MX2022014368A (https=) |
| TW (1) | TWI910174B (https=) |
| WO (1) | WO2021239082A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US20250115654A1 (en) * | 2021-11-12 | 2025-04-10 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| WO2023207106A1 (zh) * | 2022-04-29 | 2023-11-02 | 苏州星洲生物科技有限公司 | Glp-1/gip受体共激动剂、包含其的药物组合物及其用途 |
| EP4556487A1 (en) * | 2022-07-13 | 2025-05-21 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
| CN115806593B (zh) * | 2022-09-23 | 2023-09-05 | 成都普康生物科技有限公司 | 一种脂肪酸链修饰的双受体激动剂及其用途 |
| CN116120425A (zh) * | 2022-12-27 | 2023-05-16 | 南京赛诺生物技术有限公司 | 一种glp-1/gip受体双重激动剂及其应用 |
| CN118056839B (zh) * | 2023-01-17 | 2024-11-29 | 广东众生睿创生物科技有限公司 | 带有修饰结构的多肽及其应用 |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| CN116496361B (zh) * | 2023-06-25 | 2023-09-15 | 北京科翔中升医药科技有限公司 | 氘代模拟肽gip和glp-1双受体激动剂药物及用途 |
| TW202529797A (zh) * | 2023-12-12 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途 |
| WO2025242218A1 (zh) * | 2024-05-24 | 2025-11-27 | 上海翰森生物医药科技有限公司 | 一种多肽激动剂，其制备方法及医药用途 |
| CN120081924A (zh) * | 2024-07-11 | 2025-06-03 | 中国药科大学 | Glp-1r受体激动多肽化合物及其用途 |
| CN119390784A (zh) * | 2024-07-11 | 2025-02-07 | 中国药科大学 | 一种双激动多肽化合物及其医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6006118B2 (ja) * | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US9453062B2 (en) * | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| CN104583232B (zh) * | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| AU2013366692B2 (en) * | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| CN108271356A (zh) * | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | 肠降血糖素-胰岛素缀合物 |
| CN107108715A (zh) * | 2014-10-24 | 2017-08-29 | 默沙东公司 | 胰高血糖素和glp‑1受体的共激动剂 |
| WO2016131893A1 (en) * | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| US10946074B2 (en) * | 2016-03-03 | 2021-03-16 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| CN111825758B (zh) * | 2019-04-19 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
-
2021
- 2021-05-28 CN CN202180004912.4A patent/CN114222755B/zh active Active
- 2021-05-28 TW TW110119502A patent/TWI910174B/zh active
- 2021-05-28 CN CN202410666887.1A patent/CN118754965A/zh active Pending
- 2021-05-28 MX MX2022014368A patent/MX2022014368A/es unknown
- 2021-05-28 KR KR1020227043237A patent/KR20230018395A/ko active Pending
- 2021-05-28 WO PCT/CN2021/096568 patent/WO2021239082A1/zh not_active Ceased
- 2021-05-28 BR BR112022023834A patent/BR112022023834A2/pt unknown
- 2021-05-28 AU AU2021278157A patent/AU2021278157A1/en active Pending
- 2021-05-28 JP JP2022571299A patent/JP2023526973A/ja active Pending
- 2021-05-28 CN CN202410663771.2A patent/CN118530333A/zh active Pending
- 2021-05-28 CA CA3180215A patent/CA3180215A1/en active Pending
- 2021-05-28 US US17/927,304 patent/US20230190879A1/en active Pending
- 2021-05-28 EP EP21812549.0A patent/EP4159750A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526973A5 (https=) | ||
| CN107531806B (zh) | 融合蛋白 | |
| KR101352225B1 (ko) | 신규한 엑센딘 변형 및 이들의 콘쥬게이트 | |
| EP2621538B1 (en) | Engineered polypeptides having enhanced duration of action | |
| JP6412183B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
| KR101424550B1 (ko) | 지속형 인슐린 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물 | |
| JP7014515B2 (ja) | 持続型インスリンアナログ結合体及び持続型インスリン分泌ペプチド結合体を含む糖尿病治療用組成物 | |
| US9879063B2 (en) | Engineered polypeptides having enhanced duration of action and reduced immunogenicity | |
| US20140235535A1 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2018135346A5 (https=) | ||
| JP2013517307A5 (https=) | ||
| JP2012529463A (ja) | ２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ | |
| JP2023545684A5 (https=) | ||
| JP2001011095A (ja) | Ｇｌｐ−１誘導体 | |
| JP2024546026A5 (https=) | ||
| JP2023500895A5 (https=) | ||
| JP2023144098A (ja) | ポリペプチドを含む医薬組成物 | |
| CN102781458A (zh) | 多肽缀合物 | |
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| RU2025118079A (ru) | Аналог инкретина и его применение | |
| CA2950266C (en) | Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate | |
| HK40109784A (zh) | 胰岛素衍生物 | |
| HK1196624B (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| HK1188710B (en) | Engineered polypeptides having enhanced duration of action |